Nitin K Damle

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Curr Opin Pharmacol 3:386-90. 2003
  2. ncbi Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Pharmaceuticals, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Expert Opin Biol Ther 4:1445-52. 2004
  3. ncbi Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200/4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 54:11-24. 2005
  4. ncbi Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    John F DiJoseph
    Oncology Discovery Research, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 12:242-9. 2006
  5. ncbi CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 56:1107-17. 2007
  6. ncbi Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
    John F DiJoseph
    Oncology Discovery, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 10:8620-9. 2004
  7. ncbi Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples
    Erwin R Boghaert
    Wyeth Discovery Research Oncology, 401 North Middletown Rd, Pearl River, NY 10965, USA
    Cancer Chemother Pharmacol 61:1027-35. 2008
  8. ncbi Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy
    Erwin R Boghaert
    Wyeth Research, Pearl River, NY 10965, USA
    Int J Oncol 28:675-84. 2006
  9. ncbi Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts
    Erwin R Boghaert
    Wyeth Discovery Oncology and Wyeth Discovery Chemical and Screening Sciences, Pearl River, New York, USA
    Clin Cancer Res 10:4538-49. 2004
  10. ncbi Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    John F DiJoseph
    Department of Oncology Discovery, Wyeth Research, Pearl River, NY 10965, USA
    Blood 103:1807-14. 2004

Collaborators

Detail Information

Publications15

  1. ncbi Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Curr Opin Pharmacol 3:386-90. 2003
    ..Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically validated therapeutic strategy for the treatment of human cancer...
  2. ncbi Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Pharmaceuticals, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Expert Opin Biol Ther 4:1445-52. 2004
    ..A number of tumour-targeted immunoconjugates of calicheamicin are being explored preclinically at present for their therapeutic applications...
  3. ncbi Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200/4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 54:11-24. 2005
    ..Based on these results, a calicheamicin conjugate of g5/44, CMC-544, was selected for further development as a targeted chemotherapeutic agent for the treatment of B-cell malignancies...
  4. ncbi Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    John F DiJoseph
    Oncology Discovery Research, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 12:242-9. 2006
    ..CONCLUSION: The demonstration of superior antitumor activity of a combination of CMC-544 and rituximab described here provides the preclinical basis for its clinical evaluation as a treatment option for B-NHL...
  5. ncbi CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 56:1107-17. 2007
    ....
  6. ncbi Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
    John F DiJoseph
    Oncology Discovery, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 10:8620-9. 2004
    ..These results support clinical evaluation of CMC-544 in the treatment of CD22+ lymphoid malignancies...
  7. ncbi Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples
    Erwin R Boghaert
    Wyeth Discovery Research Oncology, 401 North Middletown Rd, Pearl River, NY 10965, USA
    Cancer Chemother Pharmacol 61:1027-35. 2008
    ..The method should discriminate between PK of the antibody moiety and PK of the conjugated calicheamicin (CM)...
  8. ncbi Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy
    Erwin R Boghaert
    Wyeth Research, Pearl River, NY 10965, USA
    Int J Oncol 28:675-84. 2006
    ..The results showed that using 'non-specific' immunoglobulin for passive targeting of calicheamicin might be an effective mode of cancer therapy...
  9. ncbi Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts
    Erwin R Boghaert
    Wyeth Discovery Oncology and Wyeth Discovery Chemical and Screening Sciences, Pearl River, New York, USA
    Clin Cancer Res 10:4538-49. 2004
    ..Because Le(y) is highly expressed on carcinomas of colon, breast, lung, ovary, and prostate, a CalichDMH conjugate targeting Le(y) could provide a treatment option for various cancers...
  10. ncbi Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    John F DiJoseph
    Department of Oncology Discovery, Wyeth Research, Pearl River, NY 10965, USA
    Blood 103:1807-14. 2004
    ..Thus, CD22-targeted delivery of CalichDMH is a potent and effective preclinical therapeutic strategy for BCLs. The strong antitumor profile of CMC-544 supports its clinical evaluation as a treatment option for B-lymphoid malignancies...
  11. ncbi Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Chemother Pharmacol 67:741-9. 2011
    ..Here, we describe anti-tumor efficacy of CMC-544, CHOP or CVP against human BCL xenografts...
  12. ncbi Biopharmaceutical drug discovery using novel protein scaffolds
    Davinder S Gill
    Wyeth Research, Biological Technologies 87 CambridgePark Drive, Cambridge, Massachusetts 02140, USA
    Curr Opin Biotechnol 17:653-8. 2006
    ..Further progress in the field will permit the commercially successful development of sophisticated protein therapeutics against complex disease targets...
  13. ncbi Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells
    Lyka Potla
    Oncology/Immunology Division, Wyeth-Ayerst Research, 200/4604, 401 North Middletown Road, Pearl River, NY 10965-1299, USA
    Cancer Lett 175:187-95. 2002
    ..Because the function of E-cadherin is associated with contact inhibition of HT29 cells, phosphorylation of E-cadherin and beta-catenin by activation of EphA1 is one possible mechanism by which HT29 cells alleviate contact inhibition...
  14. ncbi B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model
    Kyri Dunussi-Joannopoulos
    Department of Inflammation, Wyeth Research, Cambridge, MA, USA
    Blood 106:2235-43. 2005
    ....
  15. ncbi Antibody-drug conjugates ace the tolerability test
    Nitin K Damle
    Nat Biotechnol 26:884-5. 2008